Venezuelan Drug Firms Seek Major Price Hikes

4 November 1996

Federfarma, the Venezuelan drug industry federation, has called for for an immediate rise in drug prices of up to 80% and for a development plan enabling the drug market to be liberalized.

Federation president Raul Mejuto and colleagues from both the domestic and international industries have proposed an 80% rise for the cheapest drugs, priced below 1,000 bolivars ($0.27) per pack, with a 60% rise for those sold at below 500 bolivars, 40% for those priced at 1,000-5,000 bolivars, and 20% for those priced above 3,000 bolivars per pack.

Drugs whose prices are now controlled would be reduced, in the medium term, from 3,800 to 500 presentations based on 104 active principles, they propose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight